1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L2, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasmRecruitingPhase 32026-04-30NCT06051409